destiny pharma plc said monday the clinical and commercial opportunity of its ntcdm3 asset a drug for the treatment of clostridioides difficile infections was confirmed by a us research study and new market research the londonlisted clinicalstage biotechnology company said the results of a study undertaken by the us department of veterans affairs confirmed ntcdm3s ability to colonize the gut after antibiotic administration the company said these findings strengthened its market opportunity as they support its use following commonly used antibiotic treatments the company also said that market research undertaken in europe and north america reinforced the assets clinical support and market potential there is significant value potential in our ntcdm3 asset and we look forward to providing further updates on the regulatory and development plans throughout 2022 chief executive neil clark said shares at 0835 gmt were up 150 pence or 15 at 10050 pence